PPARG and inflammatory bowel disease: Together, these findings imply three things: (i) that PPARA and PPARG are simultaneously downregulated in IBD, (ii) that such downregulation is invariably associated with inflammation, fibrosis, and disruption of the epithelial barrier, and (iii) that simultaneous upregulation of PPARA and PPARG with agonists may restore the gut barrier.